Bicalutamide failure in prostate cancer treatment

Involvement of Multi Drug Resistance proteins

Nicola Antonio Colabufo, Vincenzo Pagliarulo, Francesco Berardi, Marialessandra Contino, Carmela Inglese, Mauro Niso, Patrizia Ancona, Giancarlo Albo, Arcangelo Pagliarulo, Roberto Perrone

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Prolonged bicalutamide treatment induced pathology regression although relapses with a more aggressive form of prostate cancer have been observed. This failure could be due to androgen receptor mutation. In the present work we hypothesized an alternative mechanism responsible for bicalutamide failure involving activity of ATP-binding cassette (ABC) pumps such as P-glycoprotein, Breast Cancer Receptor Protein (BCRP), and Multi Resistant Proteins (MRPs) that extrude the androgen antagonist from the cell membrane. As experimental models androgen-dependent (LnCap) and androgen-independent (PC-3) prostate cancer cell lines have been employed. Bicalutamide has been tested in the cell lines mentioned above in the absence and in the presence of MC18, our potent P-glycoprotein/BCRP/MRP1 inhibitor. The results displayed that bicalutamide antiproliferative effect at 72 h was ameliorated in LnCap cells (EC50 from 51.9 ± 6.1 μM to 17.8 ± 2.6 μM in the absence and in the presence of MC18, respectively) and restored in PC-3 cells (EC50 from 150 ± 2.4 μM to 60 ± 3.5 μM in the absence and in the presence of MC18, respectively). Moreover, we established the contribution of each transporter employing stable transfected cells (MDCK) overexpressing P-glycoprotein or BCRP or MRP1 pump. The results displayed that P-glycoprotein and BCRP were involved in bicalutamide efflux while MRP1 was unable to bind the antiandrogen drug.

Original languageEnglish
Pages (from-to)38-42
Number of pages5
JournalEuropean Journal of Pharmacology
Volume601
Issue number1-3
DOIs
Publication statusPublished - Dec 28 2008

Fingerprint

Multiple Drug Resistance
P-Glycoprotein
Prostatic Neoplasms
Breast Neoplasms
Androgen Antagonists
Proteins
Androgens
Cell Line
Madin Darby Canine Kidney Cells
Androgen Receptors
Theoretical Models
Adenosine Triphosphate
Cell Membrane
bicalutamide
Pathology
Recurrence
Mutation
Pharmaceutical Preparations

Keywords

  • BCRP
  • Bicalutamide
  • Calcein-AM
  • MRP1
  • P-glycoprotein

ASJC Scopus subject areas

  • Pharmacology

Cite this

Colabufo, N. A., Pagliarulo, V., Berardi, F., Contino, M., Inglese, C., Niso, M., ... Perrone, R. (2008). Bicalutamide failure in prostate cancer treatment: Involvement of Multi Drug Resistance proteins. European Journal of Pharmacology, 601(1-3), 38-42. https://doi.org/10.1016/j.ejphar.2008.10.038

Bicalutamide failure in prostate cancer treatment : Involvement of Multi Drug Resistance proteins. / Colabufo, Nicola Antonio; Pagliarulo, Vincenzo; Berardi, Francesco; Contino, Marialessandra; Inglese, Carmela; Niso, Mauro; Ancona, Patrizia; Albo, Giancarlo; Pagliarulo, Arcangelo; Perrone, Roberto.

In: European Journal of Pharmacology, Vol. 601, No. 1-3, 28.12.2008, p. 38-42.

Research output: Contribution to journalArticle

Colabufo, NA, Pagliarulo, V, Berardi, F, Contino, M, Inglese, C, Niso, M, Ancona, P, Albo, G, Pagliarulo, A & Perrone, R 2008, 'Bicalutamide failure in prostate cancer treatment: Involvement of Multi Drug Resistance proteins', European Journal of Pharmacology, vol. 601, no. 1-3, pp. 38-42. https://doi.org/10.1016/j.ejphar.2008.10.038
Colabufo, Nicola Antonio ; Pagliarulo, Vincenzo ; Berardi, Francesco ; Contino, Marialessandra ; Inglese, Carmela ; Niso, Mauro ; Ancona, Patrizia ; Albo, Giancarlo ; Pagliarulo, Arcangelo ; Perrone, Roberto. / Bicalutamide failure in prostate cancer treatment : Involvement of Multi Drug Resistance proteins. In: European Journal of Pharmacology. 2008 ; Vol. 601, No. 1-3. pp. 38-42.
@article{4f01b36b07ea4b878976b2a35a401d94,
title = "Bicalutamide failure in prostate cancer treatment: Involvement of Multi Drug Resistance proteins",
abstract = "Prolonged bicalutamide treatment induced pathology regression although relapses with a more aggressive form of prostate cancer have been observed. This failure could be due to androgen receptor mutation. In the present work we hypothesized an alternative mechanism responsible for bicalutamide failure involving activity of ATP-binding cassette (ABC) pumps such as P-glycoprotein, Breast Cancer Receptor Protein (BCRP), and Multi Resistant Proteins (MRPs) that extrude the androgen antagonist from the cell membrane. As experimental models androgen-dependent (LnCap) and androgen-independent (PC-3) prostate cancer cell lines have been employed. Bicalutamide has been tested in the cell lines mentioned above in the absence and in the presence of MC18, our potent P-glycoprotein/BCRP/MRP1 inhibitor. The results displayed that bicalutamide antiproliferative effect at 72 h was ameliorated in LnCap cells (EC50 from 51.9 ± 6.1 μM to 17.8 ± 2.6 μM in the absence and in the presence of MC18, respectively) and restored in PC-3 cells (EC50 from 150 ± 2.4 μM to 60 ± 3.5 μM in the absence and in the presence of MC18, respectively). Moreover, we established the contribution of each transporter employing stable transfected cells (MDCK) overexpressing P-glycoprotein or BCRP or MRP1 pump. The results displayed that P-glycoprotein and BCRP were involved in bicalutamide efflux while MRP1 was unable to bind the antiandrogen drug.",
keywords = "BCRP, Bicalutamide, Calcein-AM, MRP1, P-glycoprotein",
author = "Colabufo, {Nicola Antonio} and Vincenzo Pagliarulo and Francesco Berardi and Marialessandra Contino and Carmela Inglese and Mauro Niso and Patrizia Ancona and Giancarlo Albo and Arcangelo Pagliarulo and Roberto Perrone",
year = "2008",
month = "12",
day = "28",
doi = "10.1016/j.ejphar.2008.10.038",
language = "English",
volume = "601",
pages = "38--42",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Bicalutamide failure in prostate cancer treatment

T2 - Involvement of Multi Drug Resistance proteins

AU - Colabufo, Nicola Antonio

AU - Pagliarulo, Vincenzo

AU - Berardi, Francesco

AU - Contino, Marialessandra

AU - Inglese, Carmela

AU - Niso, Mauro

AU - Ancona, Patrizia

AU - Albo, Giancarlo

AU - Pagliarulo, Arcangelo

AU - Perrone, Roberto

PY - 2008/12/28

Y1 - 2008/12/28

N2 - Prolonged bicalutamide treatment induced pathology regression although relapses with a more aggressive form of prostate cancer have been observed. This failure could be due to androgen receptor mutation. In the present work we hypothesized an alternative mechanism responsible for bicalutamide failure involving activity of ATP-binding cassette (ABC) pumps such as P-glycoprotein, Breast Cancer Receptor Protein (BCRP), and Multi Resistant Proteins (MRPs) that extrude the androgen antagonist from the cell membrane. As experimental models androgen-dependent (LnCap) and androgen-independent (PC-3) prostate cancer cell lines have been employed. Bicalutamide has been tested in the cell lines mentioned above in the absence and in the presence of MC18, our potent P-glycoprotein/BCRP/MRP1 inhibitor. The results displayed that bicalutamide antiproliferative effect at 72 h was ameliorated in LnCap cells (EC50 from 51.9 ± 6.1 μM to 17.8 ± 2.6 μM in the absence and in the presence of MC18, respectively) and restored in PC-3 cells (EC50 from 150 ± 2.4 μM to 60 ± 3.5 μM in the absence and in the presence of MC18, respectively). Moreover, we established the contribution of each transporter employing stable transfected cells (MDCK) overexpressing P-glycoprotein or BCRP or MRP1 pump. The results displayed that P-glycoprotein and BCRP were involved in bicalutamide efflux while MRP1 was unable to bind the antiandrogen drug.

AB - Prolonged bicalutamide treatment induced pathology regression although relapses with a more aggressive form of prostate cancer have been observed. This failure could be due to androgen receptor mutation. In the present work we hypothesized an alternative mechanism responsible for bicalutamide failure involving activity of ATP-binding cassette (ABC) pumps such as P-glycoprotein, Breast Cancer Receptor Protein (BCRP), and Multi Resistant Proteins (MRPs) that extrude the androgen antagonist from the cell membrane. As experimental models androgen-dependent (LnCap) and androgen-independent (PC-3) prostate cancer cell lines have been employed. Bicalutamide has been tested in the cell lines mentioned above in the absence and in the presence of MC18, our potent P-glycoprotein/BCRP/MRP1 inhibitor. The results displayed that bicalutamide antiproliferative effect at 72 h was ameliorated in LnCap cells (EC50 from 51.9 ± 6.1 μM to 17.8 ± 2.6 μM in the absence and in the presence of MC18, respectively) and restored in PC-3 cells (EC50 from 150 ± 2.4 μM to 60 ± 3.5 μM in the absence and in the presence of MC18, respectively). Moreover, we established the contribution of each transporter employing stable transfected cells (MDCK) overexpressing P-glycoprotein or BCRP or MRP1 pump. The results displayed that P-glycoprotein and BCRP were involved in bicalutamide efflux while MRP1 was unable to bind the antiandrogen drug.

KW - BCRP

KW - Bicalutamide

KW - Calcein-AM

KW - MRP1

KW - P-glycoprotein

UR - http://www.scopus.com/inward/record.url?scp=56949104836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56949104836&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2008.10.038

DO - 10.1016/j.ejphar.2008.10.038

M3 - Article

VL - 601

SP - 38

EP - 42

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -